Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

130.89USD
8 Dec 2017
Change (% chg)

$2.16 (+1.68%)
Prev Close
$128.73
Open
$129.17
Day's High
$132.56
Day's Low
$129.17
Volume
316,319
Avg. Vol
474,236
52-wk High
$147.63
52-wk Low
$35.98

Select another date:

Mon, Nov 20 2017

BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran

* U.S. Food and Drug Administration (FDA) grants Alnylam breakthrough therapy designation (BTD) for Patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis with polyneuropathy

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis

BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug

* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis

BRIEF-Alnylam announces proposed public offering to raise about $675 mln

* Alnylam Pharmaceuticals announces proposed public offering of $675,000,000 of common stock

BRIEF-Alnylam announces successful outcome following FDA type A meeting

* Alnylam announces successful outcome following fda type a meeting to discuss fitusiran program in hemophilia

BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06

* Alnylam Pharmaceuticals reports third quarter 2017 financial results and highlights recent period activity

BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran

* Alnylam initiates ENVISION Phase 3 clinical study with givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias (AHPs)

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

Alnylam RNAi drug reverses progress of rare fatal disease: study

More than half of patients with a rare, rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study presented on Thursday.

Select another date: